[10] Yan M, Bian L, Hu XC, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study[J]. Transl Breast Cancer Res, 2020, 1:13. [1...
trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 14(6):461–71. doi:...
1、Guven DC, Kaya MB, Fedai B, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis. Int J Clin Oncol. 2022 Feb;27(2):332-339. 2、Junji Tsurutani, et al. Subgroup Analysis of Patients ...
[4]Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial. 2023 ASCO, Abstract 1048. [5]Jerusalem G, Park YH, Hurvitz SA, et al. Trastuzumab De...
[18] Xu B, Ma F, Ouyang Q, et al. Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J]. 2018. ...
13、Hurvitz,Sara A et al.“A Pooled Analysis of Trastuzumab Deruxtecan(T-DXd)in Patients(pts)With HER2-Positive(HER2+)Metastatic Breast Cancer(mBC)With Brain Metastases(BMs)from DESTINY-Breast(DB)-01,-02,and-03.”2023 ESMO Abstract 377O. ...
[17] Wang T, Zhang P , Di LJ,et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study. Transl Breast Cancer Res 2022 ...
de Bernardi A, Bachelot T and Larrouquère L (2024) Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature. Front. Oncol. 13:1210873...
Wildiers H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet ...
2、Ma, Fei et al. “Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.” BMJ (Clinical research ed.) vol. 383 e076065. 31 Oct....